Posted by Michael Wonder on 19 May 2020
Eiger BioPharmaceuticals announces FDA acceptance of NDA for filing with priority review of Zokinvy (lonafarnib) for treatment of progeria and progeroid laminopathies
19 May 2020 - Eiger BioPharmaceuticals today announced that the U.S. FDA accepted the new drug application for accelerated review of Zokinvy (lonafarnib) for treatment of progeria and progeroid laminopathies.
The FDA granted priority review with a Prescription Drug User Fee Act target action date of 20 November 2020.
The FDA is not currently planning to hold an advisory committee meeting to discuss this application.
